Founder Mark Kotter describes the science that has enabled bit.bio to design and manufacture virtually any cell type and characteristic from iPSCs

blonca9
May 6, 2024
1 min read

He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell type. The company is now using this to create cells for research purposes and as therapeutics.

Recent Posts

See All

RBC Global Healthcare Conference: Desk Strategist Chris McCarthy shares how institutional investors have been affected by policy and macro factors, and how they have been positioning around catalysts

RBC Global Healthcare Conference: Senior Biotech Analyst Luca Issi shares his thoughts on the current state of gene and cell therapy

RBC Global Healthcare Conference: RBC's Brian Abrahams shares his take on biotech and offers advice for companies on how to navigate these times of change

Founder Mark Kotter describes the science that has enabled bit.bio to design and manufacture virtually any cell type and characteristic from iPSCs

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight